TAGRISSO
Active Ingredient: OSIMERTINIB (OSIMERTINIB MESYLATE)
Product Overview
About TAGRISSO
TAGRISSO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) with a specific type of genetic mutation called EGFR exon 20 insertion mutation in patients with disease progression on or after a previous EGFR tyrosine kinase inhibitor (TKI) therapy.
Key Benefits & Uses
- Treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation in patients with disease progression on or after a previous EGFR tyrosine kinase inhibitor (TKI) therapy.
- May be used in combination with other medications to treat NSCLC.
Active Ingredient & Action
TAGRISSO contains the active ingredient osimertinib (osimertinib mesylate), a tyrosine kinase inhibitor that works by blocking the activity of a specific protein called EGFR, which is involved in the growth and spread of cancer cells.
Important Notes
Before taking TAGRISSO, tell your doctor about all your medical conditions, including any liver or kidney problems. TAGRISSO may cause serious side effects, including interstitial lung disease (ILD)/pneumonitis, and liver damage. Your doctor will monitor you for these side effects while you are taking TAGRISSO. Do not take TAGRISSO if you are pregnant or breastfeeding. Consult your doctor for more information.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.